probucol has been researched along with Proteinuria in 18 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 7.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| " The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group." | 5.22 | Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study. ( Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016) |
| "A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6." | 3.71 | Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. ( Breiteneder-Geleff, S; Haas, M; Holzer, H; Hörl, WH; Kerjaschki, D; Kramar, R; Mayer, G; Neuweiler, J; Neyer, U; Ratschek, M; Regele, HM; Schneider, B; Wirnsberger, G, 2002) |
| " In the present study we examined whether lipid-soluble antioxidants, probucol and vitamin E, could inhibit renal injury in rats with chronic puromycin aminonucleoside (PA) nephrosis and dietary hypercholesterolemia by protecting lipoproteins from oxidation." | 3.69 | Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. ( Chung, HK; Jeong, JY; Kim, BC; Kim, YS; Lee, HS; Zhang, YZ, 1997) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 3.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Focal segmental glomerulosclerosis is a steroid-resistant glomerular disease characterized by foot process flattening and heavy proteinuria." | 1.30 | Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. ( Binder, CJ; Exner, M; Kerjaschki, D; Weiher, H, 1999) |
| "Probucol is a bisphenolic compound that lowers serum cholesterol and also has potent antioxidant properties." | 1.28 | Effects of probucol in renal function and structure in rats with subtotal kidney ablation. ( Klahr, S; Modi, KS; Purkerson, ML; Schreiner, GF, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (77.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Chen, X | 1 |
| Cai, G | 1 |
| Zheng, Y | 1 |
| Liu, M | 1 |
| Liu, W | 1 |
| Yao, H | 1 |
| Wang, Y | 1 |
| Li, W | 1 |
| Wu, H | 1 |
| Lun, L | 1 |
| Zhang, J | 1 |
| Guan, X | 1 |
| Yin, S | 1 |
| Zhuang, X | 1 |
| Li, J | 1 |
| Liu, Y | 1 |
| Zhou, C | 1 |
| Nakao, A | 1 |
| Nosaka, K | 1 |
| Imaki, H | 1 |
| Noiri, E | 1 |
| Toda, A | 1 |
| Doi, K | 1 |
| Suzuki, Y | 1 |
| Fujita, T | 1 |
| Kimura, S | 1 |
| Kondo, S | 1 |
| Shimizu, M | 1 |
| Urushihara, M | 1 |
| Tsuchiya, K | 1 |
| Yoshizumi, M | 1 |
| Tamaki, T | 1 |
| Nishiyama, A | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Quinn, MT | 1 |
| Lambeth, DJ | 1 |
| Kagami, S | 1 |
| Ogawa, M | 1 |
| Ueda, S | 1 |
| Anzai, N | 1 |
| Ito, K | 2 |
| Ohto, M | 1 |
| Akikusa, B | 1 |
| Yamasaki, K | 1 |
| Yoshikawa, Y | 1 |
| Neale, TJ | 2 |
| Ojha, PP | 1 |
| Exner, M | 2 |
| Poczewski, H | 1 |
| Rüger, B | 1 |
| Witztum, JL | 1 |
| Davis, P | 1 |
| Kerjaschki, D | 4 |
| Hattori, M | 1 |
| Kawaguchi, H | 1 |
| Yamaguchi, Y | 1 |
| Magil, A | 1 |
| Lee, HS | 1 |
| Jeong, JY | 1 |
| Kim, BC | 1 |
| Kim, YS | 1 |
| Zhang, YZ | 1 |
| Chung, HK | 1 |
| Drukker, A | 1 |
| Eddy, AA | 1 |
| Markell, MS | 1 |
| Homel, P | 1 |
| Sumrani, N | 1 |
| Hong, JH | 1 |
| Distant, DA | 1 |
| Miles, AM | 1 |
| Sommer, BG | 1 |
| Friedman, EA | 1 |
| Binder, CJ | 1 |
| Weiher, H | 1 |
| Kodama, N | 1 |
| Otani, H | 1 |
| Yamada, Y | 1 |
| Mune, M | 1 |
| Yukawa, S | 1 |
| Haas, M | 1 |
| Mayer, G | 1 |
| Wirnsberger, G | 1 |
| Holzer, H | 1 |
| Ratschek, M | 1 |
| Neyer, U | 1 |
| Neuweiler, J | 1 |
| Kramar, R | 1 |
| Schneider, B | 1 |
| Breiteneder-Geleff, S | 1 |
| Regele, HM | 1 |
| Hörl, WH | 1 |
| Modi, KS | 1 |
| Schreiner, GF | 1 |
| Purkerson, ML | 1 |
| Klahr, S | 1 |
| Hirano, T | 2 |
| Mamo, JC | 2 |
| Nagano, S | 1 |
| Sugisaki, T | 2 |
| Ohnami, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy[NCT00050713] | Phase 2 | 12 participants (Actual) | Interventional | 2002-12-17 | Completed | ||
| Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy[NCT00977977] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Proteinuria
| Article | Year |
|---|---|
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)
Topics: Animals; Antigen-Antibody Complex; Basement Membrane; Collagen; Complement Membrane Attack Complex; | 1996 |
3 trials available for probucol and Proteinuria
| Article | Year |
|---|---|
Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Benzimidazoles; Benzoates; Blood Glucose; Chol | 2016 |
Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Glomerulonephritis; Humans; Male; M | 1995 |
Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
Topics: Actuarial Analysis; Anticholesteremic Agents; Cholesterol; Chromatography, High Pressure Liquid; Cyc | 1998 |
14 other studies available for probucol and Proteinuria
| Article | Year |
|---|---|
Effects of probucol on renal function and urinary protein excretion in spontaneously hypercholesterolemic rats fed a normal or high cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol, Dietary; Dose-Response Relationship, | 2004 |
Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Biopsy, Needle; Blotting, Western; D | 2006 |
Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Glomerulosclerosis, Focal Segmental; Hyperl | 1995 |
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antigen-Antibody Complex; Basement Membrane; Cholester | 1994 |
Probucol reduces renal injury in the ExHC rat.
Topics: Animals; Cholesterol; Electrophoresis; Food, Fortified; Hypercholesterolemia; Kidney Glomerulus; Lip | 1994 |
Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chronic Disease; Disease Models, Animal; Disease | 1996 |
Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol, Dietary; Diet; Glomerulosclerosis, Foc | 1997 |
Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol; Collagen; Female; Fibronectins; Fibros | 1998 |
Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
Topics: Aging; Albuminuria; Animals; Disease Models, Animal; Free Radical Scavengers; Glomerulosclerosis, Fo | 1999 |
Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats.
Topics: Animals; Anticholesteremic Agents; Chemokine CCL2; Cholesterol, Dietary; Foam Cells; Hypercholestero | 1999 |
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Dose-Response Relationship, Drug; Drug Administration | 2002 |
Effects of probucol in renal function and structure in rats with subtotal kidney ablation.
Topics: Animals; Atrophy; Blood Pressure; Body Weight; Cholesterol; Female; Fibrosis; Hematocrit; Kidney; Ki | 1992 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu | 1991 |
Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Male; Nephrotic Syndrome; Phenols; Probucol; Proteinuria; Puromycin Aminon | 1990 |